Amber Specialty Pharmacy

Overview

Amber Specialty Pharmacy is the Hy-Vee-owned, PBM-independent specialty pharmacy that began in transplant care and now supports oncology, rare disease, immunology, neurology, fertility, and infusion-adjacent therapies for manufacturer launches. It is headquartered in Omaha, URAC-accredited as a Rare Disease Pharmacy Center of Excellence, and was named NASP Specialty Pharmacy of the Year in 2024.

Amber is not a PBM-owned specialty pharmacy and not a narrow rare-disease-only operator. The buyer value is the combination of national dispensing, reimbursement support, clinical counseling, adherence work, and a non-PBM ownership position under Hy-Vee, with documented launch roles on Rezdiffra (NASH) and BRINSUPRI (non-CF bronchiectasis).

Specialty Pharmacy Capability Model

The framework below standardizes how Rx Almanac evaluates specialty-pharmacies capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Amber Specialty Pharmacy is evaluated as Hy-Vee-owned, PBM-independent specialty pharmacy that began in transplant care and now supports oncology, rare disease, immunology, neurology, fertility, and infusion-adjacent therapies for manufacturer launches.

Capability	Buyer should compare	Amber Specialty Pharmacy readout
Specialty dispensing and channel access	Licensed dispensing footprint, payer network access, LDD participation, referral capture, and ability to serve the target patient geography.	Core fulfillment handoff. National dispensing through URAC- and ACHC-accredited operations with 50+ limited-distribution contracts and 26 million payer lives in network coverage.
Benefits, PA, and reimbursement support	Benefit investigation, PA support, appeals coordination, copay/PAP routing, and reimbursement troubleshooting at the pharmacy edge.	Core coverage workflow. End-to-end BI, PA, and financial-assistance coordination at the pharmacy edge, called out as part of the BRINSUPRI launch support model.
Clinical therapy management and adherence	Pharmacist counseling, disease-specific protocols, refill outreach, injection training, persistence programs, and clinical escalation.	Core engagement model. Personalized clinical care, 24/7 clinical support, adherence counseling; per-therapy protocol depth should be validated by product.
Cold chain, REMS, and complex handling	Temperature control, REMS certification, hazardous/controlled-substance handling, biologics, CGT, and other special distribution requirements.	Core for biologics and rare disease. URAC Rare Disease Pharmacy Center of Excellence; confirm REMS scope and CGT handling per program.
Manufacturer data and outcomes reporting	Status feeds, dispense data, adherence/outcomes reporting, inventory visibility, and reporting cadence suitable for launch governance.	Confirm reporting layer in the RFP. Specify dispense, abandonment, refill, adherence, and PA data fields, cadence, and reconciliation rights in the SOW.
Site-of-care, infusion, or health-system coordination	Home infusion, ambulatory infusion, provider-office coordination, health-system capture, and buy-and-bill support where relevant.	Adjacent via Hy-Vee Health. Infusion and site-of-care routing references exist; confirm whether services are delivered directly or through Hy-Vee Health and partner networks.

Buyer Fit

• Launch-team fit: A manufacturer that wants a national independent specialty pharmacy in the network alongside or instead of PBM-owned options, with documented LDD launch capability for oncology, rare-disease, immunology, neurology, and other complex therapies.
• Best-fit buyers: Mid-cap pharma and biotech access teams running specialty or rare-disease launches that need transplant-grade adherence rigor and a non-PBM alignment story for payer and physician audiences.
• Less ideal fit: Products that depend mainly on PBM routing power, captive covered-life control, or formulary-adjacent rebate economics; those programs should keep PBM-owned SPs in the primary network.
• Commercial fit: Pricing is undisclosed; assume an RFP-led scope with SLAs, data feeds, launch timing, adherence services, and patient-support responsibilities defined in the agreement.
• Profile signal: A repeat LDD partner across NASH (Rezdiffra) and non-CF bronchiectasis (BRINSUPRI) within an 18-month window, with NASP Specialty Pharmacy of the Year in 2024 and 2020.
• Final diligence: Confirm LDD eligibility, payer access, hub handoffs, REMS scope, data cadence, and how payer-mandated transfers are governed when a plan requires a different specialty pharmacy.

Differentiators

• PBM-independent channel: Hy-Vee ownership gives Amber a different alignment profile than CVS Specialty, Accredo / Evernorth, and Optum Specialty.
• Transplant heritage: Amber’s transplant origin underwrites its credibility for high-touch, complex, adherence-sensitive therapy management.
• URAC Rare Disease Pharmacy Center of Excellence: Formal credentialing for the small-population, high-touch model that orphan and rare-disease launches need.
• Documented LDD launches: Rezdiffra (NASH, 2024) and BRINSUPRI (non-CF bronchiectasis, 2025) anchor the recent manufacturer-facing track record.
• NASP Specialty Pharmacy of the Year (2024, 2020): Two industry recognitions inside five years signal sustained execution rather than a one-off win.

RFP Questions

• Which limited-distribution contracts, payer networks, and REMS authorizations does Amber already hold for the product class in scope?
• How will Amber’s benefit investigation, prior authorization, financial-assistance, and abandonment-recovery workflows operate for this specific therapy?
• What is the proposed clinical protocol, pharmacist touch cadence, nursing support, and escalation model, and how does it differ from a standard specialty-pharmacy workflow?
• Which dispense, abandonment, refill, adherence, and PA data fields will Amber report to the manufacturer, at what cadence, and through what channel?
• How are services divided between Amber, Hy-Vee Health, the manufacturer’s hub, and any infusion or nursing partners?
• Which CGT, ultra-cold, REMS, or controlled-substance requirements are handled internally versus through partner SPs?
• How does Amber handle payer-mandated transfers when a plan requires a different specialty pharmacy, and what data continues to flow back to the manufacturer?

Recent Activity

• 2025-08 - Amber began dispensing BRINSUPRI (brensocatib) for non-cystic fibrosis bronchiectasis alongside PantheRx Rare Pharmacy.
• 2024-10 - Amber was named NASP Specialty Pharmacy of the Year (second time, after 2020).
• 2024-03 - Amber was selected to dispense Rezdiffra (resmetirom) for noncirrhotic NASH.
• 2022 - Amber earned the URAC Rare Disease Pharmacy Center of Excellence designation.